In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a…
By D. Mendel, A. Laird, Xiaohua Xin, S. Louie, J. Christensen, Guangmin Li, R. Schreck, T. Abrams, T. J. Ngai, Leslie B. Lee and 13 more. Clinical Cancer Research, 2003
2,027 citations recorded by the source corpus.
View Paper: https://www.semanticscholar.org/paper/5faec1d5da3bbaf1a94559dba4f1b6f4e999a46c
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
- A. Adamis
- N. Ferrara
- W. Marston Linehan
- E. Scholar
- Laura S. Schmidt
- R. Srinivasan
- A. Arora
- Rakesh K. Jain
Citations in the corpus
- Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. (2011, unknown): “Anorexia 18 (22) 16 (19) 2 (2) 17 (21) 16 (20) 1 (1)”
- The genetic basis of kidney cancer: a metabolic disease (2010, background): “(30) Axitinib and pazopanib are recently developed selective inhibitors of the VEGF receptors.”
- Ten years of anti-vascular endothelial growth factor therapy (2016, background): “…bevacizumab in the Phase III VELOUR trial on second-line metastatic colorectal cancer, although a greater incidence of Sunitinib, a broad-spectrum multi-targeted oral RTKI, prevented endothelial cell proliferation and neovascularization in a variety of human tumour lines in xenograft models 115 .”
- Role of Tyrosine Kinase Inhibitors in Cancer Therapy (2005, background): “…and Jarvis (2001); b Tibes et al. (2005); c Thomas and Grandis (2004); d Rusnak et al. (2001); e Fong et al. (1999); f Lin et al. (2002); g Mendel et al. (2003); h Wilhelm et al. (2004); i Shawver et al. (1997). at A SPE T Journals on M ay 28, 2017 jpet.aspetjournals.org D ow nloaded…”
- Sunitinib in patients with metastatic renal cell carcinoma. (2006, unknown): “Hand-foot syndrome 9 (8) 7 (7) 0 16 (15)”